Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 623,749 shares of the biotechnology company's stock after purchasing an additional 12,000 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.65% of Sarepta Therapeutics worth $75,842,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of SRPT. Steward Partners Investment Advisory LLC grew its stake in shares of Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 194 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Sarepta Therapeutics by 274.5% during the 4th quarter. Jones Financial Companies Lllp now owns 528 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 387 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after acquiring an additional 216 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $3,829,000. Finally, Amalgamated Bank grew its stake in shares of Sarepta Therapeutics by 0.5% during the 4th quarter. Amalgamated Bank now owns 46,695 shares of the biotechnology company's stock worth $5,678,000 after acquiring an additional 222 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Remove Ads

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT traded down $1.27 during trading hours on Wednesday, hitting $99.44. 204,393 shares of the company were exchanged, compared to its average volume of 909,593. The company's 50 day moving average price is $113.27 and its 200-day moving average price is $120.70. The stock has a market capitalization of $9.65 billion, a price-to-earnings ratio of 79.63 and a beta of 0.79. Sarepta Therapeutics, Inc. has a 52-week low of $97.91 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Scotiabank initiated coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They set a "sector perform" rating and a $105.00 target price for the company. Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a "hold" rating and a $136.00 target price for the company. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and an average target price of $170.41.

Insider Transactions at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.